KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,034 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 10,034 shares of KalVista Pharmaceuticals stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $15.57, for a total transaction of $156,229.38. Following the completion of the sale, the chief executive officer directly owned 442,883 shares of the company’s stock, valued at approximately $6,895,688.31. The trade was a 2.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

KalVista Pharmaceuticals Stock Performance

KALV opened at $15.77 on Wednesday. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The company’s fifty day moving average price is $15.47 and its two-hundred day moving average price is $13.94. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.23 and a 1-year high of $19.00. The company has a market cap of $797.17 million, a price-to-earnings ratio of -3.99 and a beta of -0.19.

Analyst Ratings Changes

A number of equities analysts have issued reports on KALV shares. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. HC Wainwright lifted their target price on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Finally, TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $29.40.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. Tudor Investment Corp ET AL purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth approximately $24,360,000. Vestal Point Capital LP lifted its stake in KalVista Pharmaceuticals by 152.0% in the fourth quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company’s stock valued at $30,524,000 after purchasing an additional 1,140,000 shares during the last quarter. Parkman Healthcare Partners LLC grew its holdings in KalVista Pharmaceuticals by 155.5% during the third quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after purchasing an additional 1,055,940 shares during the period. Ameriprise Financial Inc. increased its position in KalVista Pharmaceuticals by 2,258.6% in the second quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after buying an additional 905,053 shares during the last quarter. Finally, Elmind Capital LP bought a new stake in shares of KalVista Pharmaceuticals in the fourth quarter valued at $12,941,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.